| Previous Close | 75.45 |
| Open | 75.50 |
| Bid | 75.43 x 900 |
| Ask | 75.44 x 1000 |
| Day's Range | 74.72 - 75.56 |
| 52 Week Range | 68.44 - 83.78 |
| Volume | 8,441,670 |
| Avg. Volume | 12,888,422 |
| Market Cap | 191.221B |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | 27.27 |
| EPS (TTM) | 2.77 |
| Earnings Date | Jul. 29, 2021 |
| Forward Dividend & Yield | 2.60 (3.45%) |
| Ex-Dividend Date | Jun. 14, 2021 |
| 1y Target Est | 92.89 |
- Zacks
Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.
- Zacks
Merck (MRK) Signs $1.2B Deal With US for COVID-19 Therapeutic
Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.
- Motley Fool
Merck Cuts a Billion-Dollar COVID Deal
The U.S. government will pay $1.2 billion for 1.7 billion doses of Merck's experimental oral COVID-19 drug.
© 2021 Verizon Media. All rights reserved.
